scholarly journals Health Care Costs Associated with Ankylosing Spondylitis in Turkey: An Analysis from Nationwide Real-World Data

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Onur Baser ◽  
Abdulkadir Burkan ◽  
Erdem Baser ◽  
Rasim Koselerli ◽  
Emre Ertugay ◽  
...  
Keyword(s):  
Health Care ◽  
Ankylosing Spondylitis ◽  
Health Care Costs ◽  
Linear Models ◽  
Office Visit ◽  
Real World Data ◽  
Treatment Type ◽  
Comorbidity Scores ◽  
Incident Cases ◽  
Care Costs

Objectives. To explore health care costs associated with ankylosing spondylitis (AS) in Turkey.Methods. Research-identified data from a system that processes claims for all Turkish health insurance funds were analyzed. Adult prevalent and incident AS patients with two AS visits at least 60 days apart, identified between June 1, 2010 and December 31, 2010, with at least 1 year of continuous health plan enrollment for the baseline and follow-up years were included in the study. Pharmacy, outpatient, and inpatient claims were compiled over the study period for the selected patients. Generalized linear models were used to estimate the expected annual costs, controlling for baseline demographic and clinical characteristics.Results. A total of 2.986 patients were identified, of which 603 were incident cases and 2.383 prevalent cases. The mean ages were 39 and 41 years, respectively, and 44% and 38% were women for incident and prevalent cases. Prevalent patients had higher comorbidity scores (5.01 versus 2.24,P<0.001) and were more likely to be prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) (77% versus 72%,P<0.001) or biologics (35% versus 8%,P<0.006) relative to incident patients. Seventy-seven percent of prevalent patients were prescribed NSAIDs, followed by biologic and disease-modifying antirheumatic drugs (DMARDs). Total annual medical costs for incident AS patients were €2.253 and €4.233 for prevalent patients. Pharmacy costs accounted for a significant portion of total costs (88% for prevalent patient, 77% for incident patient), followed by physician office visit costs. Prior comorbidities and treatment type also significantly contributed to overall costs.Conclusion. Annual expenditures for AS patients in Turkey were comparable relative to European countries. Pharmaceutical expenditures cover a significant portion of the overall costs. Comparative effectiveness studies are necessary to further decrease health care costs of AS treatment.

scholarly journals PMS23 Total Health Care Costs Associated With Ankylosing Spondylitis Incident Cases in Turkey

2012 ◽  
Vol 15 (7) ◽  
pp. A443
Author(s):  
O. Baser ◽  
A. Burkan ◽  
E. Baser ◽  
R. Koselerli ◽  
E. Ertugay ◽  
...  
Keyword(s):  
Health Care ◽  
Ankylosing Spondylitis ◽  
Health Care Costs ◽  
Incident Cases ◽  
Care Costs

SAT0541 Analysis of Health Care Costs Associated with Ankylosing Spondylitis in Turkey

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A765.1-A765
Author(s):  
O. Baser ◽  
A. Burkan ◽  
E. Baser ◽  
R. Koselerli ◽  
E. Ertugay ◽  
...  
Keyword(s):  
Health Care ◽  
Ankylosing Spondylitis ◽  
Health Care Costs ◽  
Care Costs

scholarly journals THU0548 THE ECONOMIC BURDEN OF ANKYLOSING SPONDYLITIS IN SPAIN. RESULTS OF THE SPANISH ATLAS 2017

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 514.2-514
Author(s):  
M. Merino ◽  
O. Braçe ◽  
A. González ◽  
Á. Hidalgo-Vega ◽  
M. Garrido-Cumbrera ◽  
...  
Keyword(s):  
Health Care ◽  
Ankylosing Spondylitis ◽  
Health Care Costs ◽  
Health Care Cost ◽  
Labour Productivity ◽  
General Health Questionnaire ◽  
Indirect Costs ◽  
Productivity Losses ◽  
The Cost ◽  
Care Costs

Background:Ankylosing Spondylitis (AS) is a disease associated with a high number of comorbidities, chronic pain, functional disability, and resource consumption.Objectives:This study aimed to estimate the burden of disease for patients diagnosed with AS in Spain.Methods:Data from 578 unselected patients with AS were collected in 2016 for the Spanish Atlas of Axial Spondyloarthritis via an online survey. The estimated costs were: Direct Health Care Costs (borne by the National Health System, NHS) and Direct Non-Health Care Costs (borne by patients) were estimated with the bottom-up method, multiplying the resource consumption by the unit price of each resource. Indirect Costs (labour productivity losses) were estimated using the human capital method. Costs were compared between levels of disease activity using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score (<4 or low inflammation versus ≥4 or high inflammation) and risk of mental distress using the 12-item General Health Questionnaire (GHQ-12) score (<3 or low risk versus ≥3 or high risk).Results:The average annual cost per patient with AS in 2015 amounted to €11,462.3 (± 13,745.5) per patient. Direct Health Care Cost meant an annual average of €6,999.8 (± 9,216.8) per patient, to which an annual average of €611.3 (± 1,276.5) per patient associated with Direct Non-Health Care Cost borne by patients must be added. Pharmacological treatment accounted for the largest percentage of the costs borne by the NHS (64.6%), while for patients most of the cost was attributed to rehabilitative therapies and/or physical activity (91%). The average annual Indirect Costs derived from labour productivity losses were €3,851.2 (± 8,484.0) per patient, mainly associated to absenteeism. All categories showed statistically significant differences (p<0.05) between BASDAI groups (<4 vs ≥4) except for the Direct Non-Healthcare Cost, showing a progressive rise in cost from low to high inflammation. Regarding the 12-item General Health Questionnaire (GHQ-12), all categories showed statistically significant differences between GHQ-12 (<3 vs ≥3), with higher costs associated with higher risk of poor mental health (Table 1).Table 1.Average annual costs per patient according to BASDAI and GHQ-12 groups (in Euros, 2015)NDirect Health CostsDirect Non-Health CostsIndirect CostsTotal CostBASDAI<4917,592.0*557.32,426.5*10,575.8*≥43769,706.9*768.05,104.8*15,579.7*Psychological distress (GHQ-12)<31468,146.8*493.6*3,927.2*12,567.6*≥32609,772.9*807.2*4,512.3*15,092.5*Total5786,999.8611.33,851.211,462.3* p <0.05Conclusion:Direct Health Care Costs, and those attributed to pharmacological treatment in particular, accounted for the largest component of the cost associated with AS. However, a significant proportion of the overall costs can be further attributed to labour productivity losses.Acknowledgments:Funded by Novartis Farmacéutica S.A.Disclosure of Interests:María Merino: None declared, Olta Braçe: None declared, Almudena González: None declared, Álvaro Hidalgo-Vega: None declared, Marco Garrido-Cumbrera: None declared, Jordi Gratacos-Masmitja Grant/research support from: a grant from Pfizzer to study implementation of multidisciplinary units to manage PSA in SPAIN, Consultant of: Pfizzer, MSD, ABBVIE, Janssen, Amgen, BMS, Novartis, Lilly, Speakers bureau: Pfizzer, MSD, ABBVIE, Janssen, Amgen, BMS, Novartis, Lilly

scholarly journals PMS15 Determinants of Total Health Care Costs Associated With Ankylosing Spondylitis Prevalent Cases in Turkey

2012 ◽  
Vol 15 (7) ◽  
pp. A441
Author(s):  
O. Baser ◽  
A. Burkan ◽  
E. Baser ◽  
R. Koselerli ◽  
E. Ertugay ◽  
...  
Keyword(s):  
Health Care ◽  
Ankylosing Spondylitis ◽  
Health Care Costs ◽  
Care Costs

scholarly journals Healthcare utilisation after discharge in patients admitted with gout in Western Australia

2021 ◽  
Author(s):  
Erin Kelty ◽  
Philip Robinson ◽  
Catherine Hill ◽  
Johannes Nossent ◽  
Warren Raymond ◽  
...  
Keyword(s):  
Health Care ◽  
Health Service ◽  
Health Care Costs ◽  
Linear Models ◽  
Hospital Admissions ◽  
Healthcare Utilisation ◽  
Health Service Utilisation ◽  
Service Utilisation ◽  
Median Cost ◽  
Care Costs

Abstract Objectives Evidence suggests that gout is associated with high health care costs and that many inpatient admissions are preventable. Understanding the drivers of health care costs in patients with gout will allow more targeted intervention. The objective was to examine factors associated with high health service utilisation and costs in patients admitted to hospital with gout. Methods Hospital and emergency department data was obtained for patients who had been admitted to hospital with a diagnosis of gout for the first time between 2002 and 2009. The total number, cost and potentially preventable events for the follow-up period was calculated for up to five years post the initial gout hospitalisation. The association between patient characteristics with health service utilisation and health care costs was examined using generalised linear models. Results The cohort included 4,379 individuals, that had 22,222 ED attendances (median cost: $1,826 per patient, IQR: $433 - $4,414), and 58,920 hospital admissions (median cost: $25,009 per patient, IQR: $6,844 - $60,535). Gout was not a primary driver of ED attendances or hospitalisations. A history of smoking and comorbidities including cardiovascular disease, diabetes and mental health disorders were associated with an increase health service utilisation and costs. Conclusion The presence of comorbidities play an important role the risk of health service utilization in people with gout and represents an opportunity to both improve the health-related outcomes for these patients and reduce re-presentations and associated health care costs for the health care system.

Analysis of Health Care Costs in Elderly Patients with Multiple Chronic Conditions Using a Finite Mixture of Generalized Linear Models

2016 ◽  
Vol 26 (5) ◽  
pp. 582-599 ◽  
Author(s):  
Matthias Eckardt ◽  
Christian Brettschneider ◽  
Hendrik van den Bussche ◽  
Hans-Helmut König ◽  
Keyword(s):  
Health Care ◽  
Elderly Patients ◽  
Health Care Costs ◽  
Generalized Linear Models ◽  
Chronic Conditions ◽  
Linear Models ◽  
Finite Mixture ◽  
Multiple Chronic Conditions ◽  
Care Costs

scholarly journals PMS20 Total Health Care Costs Associated With Rheumatoid Arthritis Incident Cases in Turkey

2012 ◽  
Vol 15 (7) ◽  
pp. A442
Author(s):  
O. Baser ◽  
A. Burkan ◽  
E. Baser ◽  
R. Koselerli ◽  
E. Ertugay ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Health Care ◽  
Health Care Costs ◽  
Incident Cases ◽  
Care Costs
Sign in / Sign up

Export Citation Format

Share Document